Clinical trial
Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
NCT00276549 · Case Comprehensive Cancer Center, Other · Completed
Key facts
| NCT number | NCT00276549 |
|---|---|
| Title | Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer |
| Official title | Phase II Trial of Gemcitabine And Docetaxel In Androgen-Independent Metastatic Prostate Cancer |
| Lead sponsor | Case Comprehensive Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, gemcitabine hydrochloride |
| Enrollment | 35 |
| Start date | Oct 1, 2005 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jan 13, 2006 |
| Last update posted | Jan 31, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: